Establishment Labs (NASDAQ:ESTA) Stock Price Up 7% – Here’s What Happened

Establishment Labs Holdings Inc. (NASDAQ:ESTA) shares were up 7% during trading on Monday . The company traded as high as $73.13 and last traded at $72.93. Approximately 83,325 shares changed hands during trading, a decline of 83% from the average daily volume of 478,830 shares. The stock had previously closed at $68.15.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ESTA. Canaccord Genuity Group raised their target price on Establishment Labs from $72.00 to $85.00 and gave the company a “buy” rating in a research note on Wednesday, December 17th. Weiss Ratings reissued a “sell (e+)” rating on shares of Establishment Labs in a research note on Monday, December 29th. Wall Street Zen upgraded shares of Establishment Labs from a “sell” rating to a “hold” rating in a research report on Sunday, October 19th. BTIG Research lifted their price target on shares of Establishment Labs from $81.00 to $86.00 and gave the stock a “buy” rating in a research report on Wednesday, December 31st. Finally, Citigroup boosted their price target on shares of Establishment Labs from $62.00 to $75.00 and gave the company a “neutral” rating in a report on Thursday, December 11th. Six analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $78.86.

Establishment Labs Stock Performance

The company has a debt-to-equity ratio of 15.06, a current ratio of 3.33 and a quick ratio of 2.10. The company has a market cap of $2.01 billion, a P/E ratio of -24.34 and a beta of 0.99. The stock’s 50-day moving average price is $70.15 and its 200-day moving average price is $54.48.

Establishment Labs (NASDAQ:ESTA) last released its earnings results on Wednesday, November 5th. The company reported ($0.38) earnings per share for the quarter, topping the consensus estimate of ($0.54) by $0.16. The firm had revenue of $53.78 million during the quarter, compared to analysts’ expectations of $52.28 million. Establishment Labs had a negative return on equity of 235.45% and a negative net margin of 43.45%.The company’s quarterly revenue was up 33.8% on a year-over-year basis. During the same period in the prior year, the company earned ($0.59) earnings per share. Equities analysts anticipate that Establishment Labs Holdings Inc. will post -2.41 EPS for the current year.

Institutional Trading of Establishment Labs

Several large investors have recently made changes to their positions in ESTA. Quarry LP purchased a new position in shares of Establishment Labs during the third quarter valued at approximately $34,000. State of Wyoming purchased a new stake in shares of Establishment Labs during the third quarter valued at approximately $71,000. Osaic Holdings Inc. lifted its holdings in Establishment Labs by 900.0% during the second quarter. Osaic Holdings Inc. now owns 2,000 shares of the company’s stock worth $85,000 after acquiring an additional 1,800 shares during the period. CWM LLC boosted its position in Establishment Labs by 45.9% in the second quarter. CWM LLC now owns 2,182 shares of the company’s stock worth $93,000 after purchasing an additional 686 shares during the last quarter. Finally, Truist Financial Corp bought a new position in Establishment Labs in the 4th quarter valued at $200,000. 72.91% of the stock is currently owned by institutional investors and hedge funds.

About Establishment Labs

Establishment Labs Holdings Inc is a global medical technology company specializing in the design, development and manufacture of silicone gel breast implants for aesthetic and reconstructive surgery. The company’s proprietary portfolio is built around patient-focused safety, customization and innovation, offering solutions intended to enhance surgical outcomes and support clinical traceability.

The company’s flagship products fall under the Motiva® brand, which includes a range of ergonomic and round breast implants featuring SilkSurface® texturing and an embedded Q Inside® Safety microtransponder for unique implant identification.